Cognitive Outcomes in Stable Renal Transplant Patients Switched fromTacrolimus to Envarsus XR™

Phase 4 Completed 56 enrolled Vanderbilt University Medical Center Veloxis Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess cognitive outcome and quality of life in stable renal transplant patients treated with twice daily tacrolimus at baseline and after switching to Envarsus XL. The study is designed to see if switching patients from Tacrolimus to Envarsus treatment improves cognitive function.

Timeline

Start: 2021-06-22
Primary completion: 2025-01-01
Completion: 2025-10-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tacrolimus	Small molecule	—	—

Indications

No indication recorded.